Iron plays a critical role in two processes of great importance in cardiovascular diseases: vascular smooth muscle proliferation and reperfusion injury. We have isolated, synthesized and completed highly promising pilot studies on a family of iron chelators,exochelins secreted by Mycobacterium tuberculosis. They block redox reactions and are unique among chelators in that they are lipid soluble, a property that permits them to rapidly enter cells and be physiologically active at extremely low concentrations. In the desferri-form, exochelins prevent damage by reactive oxygen species to cultured cardiac myocytes, reperfusion injury in isolated rabbit hearts and proliferation of cultured human vascular smooth muscle cells (VSMCs). We propose to elucidate the molecular mechanisms by which iron chelation with lipid-soluble exochelins prevent VSMC growth. In cultured human VSMCs we will test the hypothesis that exochelins block progression through the cell cycle at both the G1 and S phases by inhibiting activity of cyclin-dependent kinases. We propose that this occurs through upregulation of inhibitory proteins, particularly p21. We will examine the uptake and intracellular distribution of exochelins and the extent to which they influence VSMC growth through interruption of redox signaling. In separate studies we will assess whether exochelins given intramurally or intracoronary will prevent coronary artery restenosis due to VSMC proliferation following angioplasty in a porcine model. We will also assess the effects of desferri-exochelins given during reperfusion on myocardial infarct size, normalized for volume at risk and collateral blood flow, in a rigorous canine model involving 90 min of coronary occlusion and 48 hours of reperfusion. Finally we will examine whether desferri-exochelins prevent apoptosis, a genetically programmed mechanism of cell death that has been associated with reperfusion injury. We believe that exochelins have extraordinary potential for prevention of vascular and reperfusion injury, and are uniquely suitable for understanding the role of iron in these processes. This project would offer important mechanistic information at the molecular level and critical potential proof of principle for important therapeutic applications. We submit that our considerable progress to date and our unique familiarity with exochelins establishes that we have the capabilities to complete these exciting studies.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL055291-06
Application #
6351492
Study Section
Cardiovascular and Pulmonary Research A Study Section (CVA)
Program Officer
Balshaw, David M
Project Start
1996-02-01
Project End
2003-01-31
Budget Start
2001-02-01
Budget End
2002-01-31
Support Year
6
Fiscal Year
2001
Total Cost
$269,160
Indirect Cost
Name
University of Colorado Denver
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
065391526
City
Aurora
State
CO
Country
United States
Zip Code
80045
Horwitz, Lawrence D; Horwitz, Marcus A (2014) The exochelins of pathogenic mycobacteria: unique, highly potent, lipid- and water-soluble hexadentate iron chelators with multiple potential therapeutic uses. Antioxid Redox Signal 21:2246-61
Ambler, S Kelly; Hodges, Yvonne K; Jones, Gayle M et al. (2008) Prolonged administration of a dithiol antioxidant protects against ventricular remodeling due to ischemia-reperfusion in mice. Am J Physiol Heart Circ Physiol 295:H1303-H1310
Pahl, Paula M B; Reese, Sara M; Horwitz, Lawrence D (2007) A lipid-soluble iron chelator alters cell cycle regulatory protein binding in breast cancer cells compared to normal breast cells. J Exp Ther Oncol 6:193-200
Hodges, Yvonne K; Weinberger, Howard D; Stephens, Janet et al. (2006) Desferri-Exochelin, a lipid-soluble, hexadentate iron chelator, effectively removes tissue iron. Transl Res 148:63-71
Hodges, Yvonne K; Reese, Sara M; Pahl, Paula M B et al. (2005) Paradoxical effects of iron chelation on growth of vascular endothelial cells. J Cardiovasc Pharmacol 45:539-44
Pahl, Paula M B; Horwitz, Lawrence D (2005) Cell permeable iron chelators as potential cancer chemotherapeutic agents. Cancer Invest 23:683-91
Hodges, Yvonne K; Antholine, William E; Horwitz, Lawrence D (2004) Effect on ribonucleotide reductase of novel lipophilic iron chelators: the desferri-exochelins. Biochem Biophys Res Commun 315:595-8
Horwitz, L D; Sherman, N A (2001) Bucillamine prevents myocardial reperfusion injury. J Cardiovasc Pharmacol 38:859-67
Pahl, P M; Horwitz, M A; Horwitz, K B et al. (2001) Desferri-exochelin induces death by apoptosis in human breast cancer cells but does not kill normal breast cells. Breast Cancer Res Treat 69:69-79
Rosenthal, E A; Bohlmeyer, T J; Monnet, E et al. (2001) An iron-binding exochelin prevents restenosis due to coronary artery balloon injury in a porcine model. Circulation 104:2222-7

Showing the most recent 10 out of 17 publications